A new study may pave the way toward more personalized treatments for patients with high-risk bladder cancer, according to a study published in European Urology.
Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary diseaseFDA ...
In patients with very high risk, high grade T1 with CIS NMIBC, the possible value of adding immune checkpoint blockade to BCG has not been defined.
A new survey undertaken by the Harris Poll for Johnson & Johnson has shown how standard forms of surgery and treatment for ...
Adding immunotherapy to standard treatment for non-muscle invasive bladder cancer (NMIBC) achieved complete response (CR) in ...
Interventions for patients with asymptomatic pre-HF may be important in reducing the incidence of clinically overt HF, including HF with preserved ejection fraction (HFpEF). Mirabegron activates the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results